Simulations Plus (NASDAQ:SLP) Posts Earnings Results

Simulations Plus (NASDAQ:SLP) released its quarterly earnings results on Wednesday. The technology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02, Briefing.com reports. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The company had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. During the same period in the previous year, the firm earned $0.18 EPS. Simulations Plus’s revenue was up 19.9% on a year-over-year basis. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Down 0.9 %

Shares of Simulations Plus stock traded down $0.28 during trading on Friday, hitting $30.68. The stock had a trading volume of 276,597 shares, compared to its average volume of 130,076. The stock has a 50 day simple moving average of $33.20 and a 200 day simple moving average of $40.76. The company has a market capitalization of $613.91 million, a PE ratio of 64.50 and a beta of 0.69. Simulations Plus has a 1 year low of $29.37 and a 1 year high of $51.22.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $39.63, for a total value of $792,600.00. Following the transaction, the director now directly owns 3,521,592 shares of the company’s stock, valued at $139,560,690.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 60,750 shares of company stock valued at $2,145,055 over the last ninety days. Corporate insiders own 20.90% of the company’s stock.

Analyst Ratings Changes

SLP has been the topic of a number of recent analyst reports. Craig Hallum restated a “buy” rating and set a $56.00 price target on shares of Simulations Plus in a research report on Wednesday, July 3rd. JMP Securities assumed coverage on shares of Simulations Plus in a research note on Tuesday, July 16th. They issued a “market perform” rating on the stock. KeyCorp assumed coverage on shares of Simulations Plus in a research note on Monday, July 29th. They issued an “overweight” rating and a $47.00 price objective on the stock. BTIG Research lowered their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Thursday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Simulations Plus currently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.